Your browser doesn't support javascript.
loading
COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis.
Flacco, Maria Elena; Acuti Martellucci, Cecilia; Baccolini, Valentina; De Vito, Corrado; Renzi, Erika; Villari, Paolo; Manzoli, Lamberto.
Afiliación
  • Flacco ME; Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy.
  • Acuti Martellucci C; Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy.
  • Baccolini V; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • De Vito C; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Renzi E; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Villari P; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Manzoli L; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Front Med (Lausanne) ; 9: 1023507, 2022.
Article en En | MEDLINE | ID: mdl-36438045
The addictive protection against SARS-CoV-2 reinfection conferred by vaccination, as compared to natural immunity alone, remains to be quantified. We thus carried out a meta-analysis to summarize the existing evidence on the association between SARS-CoV-2 vaccination and the risk of reinfection and disease. We searched MedLine, Scopus and preprint repositories up to July 31, 2022, to retrieve cohort or case-control studies comparing the risk of SARS-CoV-2 reinfection or severe/critical COVID-19 among vaccinated vs. unvaccinated subjects, recovered from a primary episode. Data were combined using a generic inverse-variance approach. Eighteen studies, enrolling 18,132,192 individuals, were included. As compared to the unvaccinated, vaccinated subjects showed a significantly lower likelihood of reinfection (summary Odds Ratio-OR: 0.47; 95% CI: 0.42-0.54). Notably, the results did not change up to 12 months of follow-up, by number of vaccine doses, in studies that adjusted for potential confounders, adopting different reinfection definitions, and with different predominant strains. Once reinfected, vaccinated subjects were also significantly less likely to develop a severe disease (OR: 0.45; 95% CI: 0.38-0.54). Although further studies on the long-term persistence of protection, under the challenge of the new circulating variants, are clearly needed, the present meta-analysis provides solid evidence of a stronger protection of hybrid vs. natural immunity, which may persist during Omicron waves and up to 12 months.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Front Med (Lausanne) Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Front Med (Lausanne) Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza